Medtech Actuator Menzies Science Fellowship

MedTech Actuator Menzies Fellowship

  • Offered to 2 prestigious scientists
  • Each Fellowship valued at $70,000 including a $20,000 stipend
  • 12-month Fellowship program (approx. 2-3 days/month) delivered through the industry-led accelerator, leadershIp programs and mentoring program
  • Announced at the MTAC gala dinner or another appropriate event

2021 Medtech Actuator Menzies Science Fellows:

Meet Dr Warwick Nesbitt. Dr Warwick Nesbitt is the Laboratory Head of the Haematology Micro-platforms Group within the Australian Centre for Blood Disease, Monash University. His multidisciplinary group focusses on the development of novel lab-on-a-chip technologies with applications to: basic haematology / cell biology research. new diagnostics in thrombosis and haemostasis and new antithrombotic drug discovery.

“A key inspiration for our technology is the prevalence and impact that cardiovascular diseases, particularly heart attack and stroke have on the community. Having had family members’ quality of life impacted through the devastating effects of stroke I am keenly aware of the need for better diagnostics and therapeutics in this area of medicine. My hope is that by developing better tests of blood function we can improve the clinical management of cardiovascular disease patients. Through the MedTech Actuator Menzies Fellowship I hope to develop a better understanding of the MedTech landscape in Australia and internationally, and to access the experience, expertise, and networks necessary to commercialise our lab-on-a-chip technologies. I am excited and looking forward to the opportunity to be mentored by experts in MedTech commercialisation and translation.” -Dr Warwick Nesbitt

Learn more about Warwick here.

Meet Dr Gregory Stewart. Dr Gregory Stewart is working at the interface of academia and the pharmaceutical industry to drive programs to discover better medicines.

“Mental health issues have touched my personal life as they have touched the lives of the vast majority of people.The current medicines to treat diseases, like schizophrenia, are far from ideal. My drive is to create new medicines for psychiatric diseases to improve the quality of life of those affected.

Schizophrenia is a disease that has no effective treatment options. I believe my project can create a therapeutic for schizophrenia with vastly improved efficacy and greatly reduced side effect profile – thereby improving patient outcomes.

Through the MedTech Actuator Menzies Fellowship I hope to connect with industry leaders in Australia and the region, whilst gaining a deeper understanding on the inner workings of the Australian BioTech industry. Becoming a MedTech Actuator Menzies Fellow will form a critical component in the transition I wish to make into an industry-oriented position and Australian BioTech.” -Dr Gregory Stewart

Learn more about Gregory here.

2020 Medtech Actuator Menzies Science Fellows:

Associate Professor Jeremy Crook is Chief Investigator for the Synthetic Biosystems theme of the ARC Centre of Excellence for Electromaterials Science, and Principal Fellow at the University of Wollongong. Jeremy and his team’s research integrates front-line technologies stem cells, innovative biomaterials, 3D bioprinting and bioelectrics, and is establishing Australia’s position as a global leader in innovative tissue engineering and electroceuticals for advanced research and medicine.

How will this fellowship help me? The Fellowship will be important to achieving my aspirations for translating what began as merely an idea conceived only 3 years ago by myself and team member Dr Eva Tomaskovic-Crook into a clinically useful medical technology. The concept was born out of a desire to develop a flexible and multifunctional platform for electrically stimulating cells and tissues, first and foremost in the lab, but also motivated by the possibility of adapting the technology for electroceuticals. The latter ambition has now become a priority and so the timing of the Fellowship couldn’t be better. It is an opportunity for me to learn from leading experts in MedTech commercialisation, as well as connect with others in the broader ecosystem. By increasing our commercialisation focus now, I hope to accelerate translation of a “first cab off the rank” so to speak, in the form of a world-first wireless electric nerve-guide for peripheral nerve repair.

I’m eager to better understand what it will take to move a medical technology innovation, and more specifically our particular innovation, through commercialisation and onto the market.

Learn more about Jeremy here.

Dr Chris McCarthy is a Senior Lecturer in Computer Science at Swinburne University of Technology. Since receiving his PhD from the Australian National University in 2010, Chris has been at the forefront of bio-inspired computer vision, in particular its application to sensory augmentation for low vision assistive devices; most significantly as part of Australia’s “bionic eye” project (Bionic Vision Australia) where Chris contributed significantly to the development and evaluation of pioneering algorithms aiming to enhance clinical benefits for retinal implant recipients. Chris has also led the development of a robotic aid for paediatric rehabilitation now deployed for use in Melbourne’s Royal Children’s Hospital, and has contributed significantly to a range of industry—partnered projects spanning a wide range of sectors including health, agriculture and Smart Cities.

How will this fellowship help me? As an academic researcher, I love solving problems but get most satisfaction in seeing theoretical solutions translate to real outcomes. This fellowship will give me the much-needed mentorship, focus and structured support I need to truly realise this for CueSleeve. It will take our device from proof of concept to a commercially viable product that is attractive to investors, has a business plan in place to get us there, and has high visibility within Australia’s vibrant Med-Tech sector. I am excited to learn about entrepreneurship and business from the experts, and to bring this project, already multiple years in the making, out of the lab and into the hands of people we believe it can truly benefit.

Learn more about Chris here.

Latest News

Follow Us